Moreover, varlitinib more effectively inhibits tau-induced gliosis, tau phosphorylation and tau kinase DYRK1A expression in the early stage of tauopathy than in the middle stage of tauopathy in tau-overexpressing PS19 mice. Here, DYRK1A is linked to tauopathy.